Treatment of Papulopustular Rosacea

Severity-Based Treatment Algorithm

The British Journal of Dermatology recommends initiating treatment for mild papulopustular rosacea with topical ivermectin 1% cream or azelaic acid 15% gel/foam 1, 2, 3
For moderate-to-severe papulopustular rosacea, the British Journal of Dermatology suggests combination therapy with oral doxycycline 40 mg modified-release plus a topical agent (ivermectin or azelaic acid) 1, 2, 3, 5
The 40 mg modified-release formulation of doxycycline provides anti-inflammatory activity without antibiotic effects, reducing gastrointestinal side effects and antibiotic resistance concerns 4, 5

Ivermectin demonstrates superior efficacy compared to metronidazole in head-to-head trials, with 83% lesion reduction versus 73.7% at 16 weeks 4
Encapsulated benzoyl peroxide 5% offers the most rapid onset, with significant improvement by week 2 and sustained efficacy through 52 weeks 4, 3

All patients require general skincare, including daily sun protection with SPF 30+, gentle non-medicated cleansers, moisturizers to support skin barrier function, and trigger avoidance (spicy foods, alcohol, extreme temperatures) 1, 2, 3

Without maintenance therapy, up to two-thirds of patients relapse when treatment is discontinued, and continuing the minimum treatment necessary to maintain remission is recommended 3, 5
Topical agents alone may suffice for maintenance after initial combination therapy, and long-term doxycycline 40 mg has demonstrated safety for extended use 1, 5

If first-line treatment fails after adequate duration, switching to an alternative first-line topical agent or adding oral doxycycline 40 mg is recommended 1, 3
For severe refractory disease, considering oral isotretinoin is an option 3

Treating based on traditional rosacea subtypes should be avoided, and a phenotype-based approach targeting specific presenting features should be used instead 3
Using traditional non-encapsulated benzoyl peroxide formulations should be avoided, and only E-BPO 5% is FDA-approved for rosacea with reduced irritation 5
Discontinuing treatment prematurely leads to false treatment failures, and counseling patients about photosensitivity with doxycycline and contraindication in pregnancy, nursing, and children under 8 years is necessary 3, 5